Ghent University Academic Bibliography

Miscellaneous
open access

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022)

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, An M. T. Van Nufel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens (UGent) , Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, et al.

(2024) CANCER IMMUNOLOGY IMMUNOTHERAPY. 74(1).

Add to list

Journal Article
A1
open access

Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial

Emiel De Jaeghere (UGent) , Hannelore Hamerlinck (UGent) , Sandra Tuyaerts, Lien Lippens (UGent) , An M.T. Van Nuffel, Regina Baiden-Amissah, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, et al.

(2024) GYNECOLOGIC ONCOLOGY. 191. p.275-286

Add to list

Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1) : final survival analysis of a randomised, controlled, phase 3 trial

S Lot Aronson, Marta Lopez-Yurda, Simone N Koole, Jules H Schagen van Leeuwen, Hendrik W R Schreuder, Ralph H M Hermans, Ignace H J T de Hingh, Mignon D J M van Gent, Henriëtte J G Arts, Maaike A P C van Ham, et al.

(2023) LANCET ONCOLOGY. 24(10). p.1109-1118

Add to list

Journal Article
A1
open access

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, An M. T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens (UGent) , Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, et al.

(2023) CANCER IMMUNOLOGY IMMUNOTHERAPY. 72(2). p.475-491

Add to list

2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer : the PRIMMO phase II trial

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, Ann M.T. van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, et al.

(2022) INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. In International Journal of Gynecological Cancer 32(Supplement 2). p.A187-A188

Add to list

Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer : a study of the Belgian and Luxembourg Gynaecological Oncology Group

Ignace Vergote, Els Van Nieuwenhuysen, Stefanie De Waele, Christof Vulsteke, Caroline Lamot, Heidi Van den Bulck, Nele Claes, Marie-Pascale Graas, Guy Debrock, Isabelle Spoormans, et al.

(2022) INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 32(6). p.753-760

Add to list

Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer : results from the phase III OVHIPEC trial

Simone N. Koole, Philip C. Schouten, Jan Hauke, Roel J. C. Kluin, Petra Nederlof, Lisa K. Richters, Gabriele Krebsbach, Karolina Sikorska, Maartje Alkemade, Mark Opdam, et al.

(2022) INTERNATIONAL JOURNAL OF CANCER. 151(8). p.1394-1404

Add to list

Standard of care in 2021 for patients with ovarian cancer in Belgium

Ignace Vergote, Hannelore Denys (UGent) , Jacques De Grève, Christine Gennigens, Koen Van de Vijver (UGent) , Joseph Kerger, Peter Vuylsteke and Jean-Francois Baurain

(2021) BELGIAN JOURNAL OF MEDICAL ONCOLOGY. 15(6). p.286-291

Add to list

Journal Article
A1
open access

Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19 : a nationwide, population-based analysis

Evandro de Azambuja, Mariana Brandao, Hans Wildiers, Annouschka Laenen, Sandrine Aspeslagh, Christel Fontaine, Joelle Collignon, Willem Lybaert, Jolanda Verheezen, Annemie Rutten, et al.

(2020) ESMO OPEN. 5(5).

Add to list

Journal Article
A1
open access

PRIMMO study protocol : a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer

Sandra Tuyaerts, An MT Van Nuffel, Eline Naert (UGent) , Peter A Van Dam, Peter Vuylsteke, Alex De Caluwé, Sandrine Aspeslagh, Piet Dirix, Lien Lippens (UGent) , Emiel De Jaeghere (UGent) , et al.

(2019) BMC CANCER. 19.

Academic Bibliography

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022)

Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial

Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1) : final survival analysis of a randomised, controlled, phase 3 trial

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study

2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer : the PRIMMO phase II trial

Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer : a study of the Belgian and Luxembourg Gynaecological Oncology Group

Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer : results from the phase III OVHIPEC trial

Standard of care in 2021 for patients with ovarian cancer in Belgium

Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19 : a nationwide, population-based analysis

PRIMMO study protocol : a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer

Contents

Support

Contact